Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

Publisher： John Wiley & Sons Inc

E-ISSN： 2326-5205|70|1|40-48

ISSN： 2326-5191

Source： ARTHRITIS & RHEUMATOLOGY, Vol.70, Iss.1, 2018-01, pp. : 40-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1562-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to Jani et al. A prospective, randomized, doubleblind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 20, Iss. 11, 2017-11 ,pp. : 1791-1791

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 10, 2010-09 ,pp. : 504-511

Karger

Access to resources Recommend Favorite

Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 9, 2015-09 ,pp. : 1742-1749

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study

By Krieckaert Charlotte L. M.  

British Journal of Rheumatology , Vol. 52, Iss. 3, 2013-03 ,pp. : 547-553

Oxford University Press

Access to resources Recommend Favorite